Prevaccination Glucose Time in Range Correlates With Antibody Response to SARS-CoV-2 Vaccine in Type 1 Diabetes
Authors' conclusion
In T1D, glucose profile during the 2 weeks preceding vaccination is associated with stronger spike antibody binding and neutralization, highlighting a role for well-controlled blood glucose in vaccination efficacy.
Study context
- Population
- Patients with T1D scheduled to receive 2 doses of BNT162b2, 21 days apart
- Participants
- 26 patients
- Exposure
- Prevaccination glucose control vs antibody response to BNT162b2
- Outcome
- Antibody response after vaccination (spike IgG; neutralization), by prevaccination glucose control
Methodological detailssingle-group, 6-month follow-up
- Single-group
- 6-month follow-up
Main finding
As reported in the abstract
Prevaccination glucose control vs postvaccine spike IgG
- Prevaccination hemoglobin A1c (HbA1c) vs postvaccine spike Immunoglobulin G (IgG) (unrelated)
- r = −0.33; P = .14
- Time in range (TIR) in 2 weeks before BNT162b2 vs postvaccine IgG
- r = 0.75; P = .02
- TAR in 2 weeks before BNT162b2 vs postvaccine IgG
- r = −0.81; P = .008
- Meeting prevaccination TIR target (≥ 70%): stronger neutralizing antibody titers, regardless of HbA1c
- P < .0001
- Meeting prevaccination TAR target (≤ 25%): stronger neutralizing antibody titers, regardless of HbA1c
- P = .008
Observational data: associations, not effects.
Further findings
Glucose control along study time frame vs IgG response during follow-up · 6 months follow-up
- TIR vs IgG
- r = 0.93; P < .0001
- TAR vs IgG
- r = −0.84; P < .0001
Original publication
Prevaccination Glucose Time in Range Correlates With Antibody Response to SARS-CoV-2 Vaccine in Type 1 Diabetes. J Clin Endocrinol Metab. Published 6 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →